Cigna reported strong Q2 2026 results with EPS ($7.78) and revenue ($71.7B) exceeding expectations, driven by robust performance in both Evernorth and Cigna Healthcare. Management raised full-year EPS guidance to 'at least $30.45', citing strength in specialty pharmacy and disciplined pricing, while noting continued elevated medical cost trends and moderating GLP-1 growth. Raised FY2026 EPS guidance to floor of $30.45, driven by strong H1 performance.
Buzzberg readRaised full-year EPS guidance to at least $30.45Cigna reported strong Q2 2026 results with EPS ($7.78) and revenue ($71.7B) exceeding expectations, driven by robust performance in both Evernorth and Cigna Healthcare. Management raised full-year EPS guidance to 'at least $30.45', citing strength in specialty pharmacy and disciplined pricing, while noting continued elevated medical cost trends and moderating GLP-1 growth. Raised FY2026 EPS guidance to floor of $30.45, driven by strong H1 performance.Read full analysisCollapse analysis
Cigna reported strong Q2 2026 results with EPS ($7.78) and revenue ($71.7B) exceeding expectations, driven by robust performance in both Evernorth and Cigna Healthcare. Management raised full-year EPS guidance to 'at least $30.45', citing strength in specialty pharmacy and disciplined pricing, while noting continued elevated medical cost trends and moderating GLP-1 growth. Raised FY2026 EPS guidance to floor of $30.45, driven by strong H1 performance.
Evernorth specialty and care services earnings grew 22% YoY, boosted by faster adoption of biosimilars/specialty generics and Shields Health Solutions investment.
PBM (Pharmacy Benefit Services) earnings declined YoY to $609M due to large client renewals and Signature model transition investments.
Cigna Healthcare earnings grew 17% YoY; MCR came in at 84.5% (slightly favorable vs expectations).
Revenue$71.668B
+5% QoQ
EPS$7.78
-0% QoQ
Gross margin20.88%
reported
Op margin3.73%
reported
What changed this quarter
01
Guidance
Raised full-year EPS guidance to at least $30.45
Guidance tone
02
Demand
2027 selling season strongest in years
Management repeatedly expressed confidence in strong execution, raised EPS guidance, and highlighted robust selling season and strategic momentum.
03
Product Launch
Signature PBM model generating significant early interest
Evernorth specialty and care services earnings grew 22% YoY, boosted by faster adoption of biosimilars/specialty generics and Shields Health Solutions investment.
04
Margins
Specialty generics adoption exceeded 80% for newer products
Reported gross margin was 20.88%, reinforcing the quarter's better-than-guided profitability.
AI, capex & demand read
AI
Platform & monetization
Management emphasized AI's role in driving affordability and personalized care, citing specific programs (Pharmacy Forward, AI-enabled care coordination) that reduce time to therapy, cut clinician documentation time, and expand support to more customers with complex health needs, with measurable cost savings.
Demand
Bookings & conversion
2027 selling season strongest in years. Management repeatedly expressed confidence in strong execution, raised EPS guidance, and highlighted robust selling season and strategic momentum.
Capex
Investment and capacity
Capital expenditure is not discussed explicitly, but management noted ongoing investments in the Signature pharmacy model and other growth initiatives, with transition expenses expected to continue through 2027 before ramping down.
Tone · Confident
Management repeatedly expressed confidence in strong execution, raised EPS guidance, and highlighted robust selling season and strategic momentum.
Supply-chain alpha
A1
Specialty generic penetration exceeded 80% for newer products during the quarter, and biosimilar/specialty generic adoption was faster than expected.
“Notably, specialty generic penetration exceeded 80% for newer products during the quarter.”
Moderating GLP-1 growth rates with slight decline in coverage levels; Cigna omitted GLP-1 weight loss drugs from its own employee plan citing affordability.
“We did make the difficult decision during 2026 to discontinue financial support for GLP-1 drugs for weight management within our own employee health plan.”
The IDR (Independent Dispute Resolution) process saw $15 billion in healthcare spending processed through it in 2025, viewed as mostly wasteful/abusive by management.
“2025 alone, the research that was published showed $15 billion healthcare spending across the industry was processed through the IDR mechanism and we view much of that spending as wasteful or abusive.”
Moderating GLP-1 growth rates with slight decline in coverage levels; Cigna omitted GLP-1 weight loss drugs from its own employee plan citing affordability. — Signals potential top-line pressure for GLP-1 manufacturers if large employers follow suit; however, this is offset by the specialty business outperformance.
Thank you. Cigna ended employee coverage of GLP-1 for Wago being debt-bound on July 1, citing rising availability and new options. Are you seeing that same sort of driver being reflected in your mid-year updates or your early 2027 renewal conversations, or has there been more pushback just on direct costs rather than the new oral entrants? And then how does that mix of drivers interact with how you see growth, transfer, and circle going forward. Thanks.
Thanks, Sarah. I'll attempt to hit the different components there. If I miss anything, please let me know. So starting with the GLP-1 coverage within our employee health plan, just like other large employers in the US, we're faced with constant trade-off decisions related to the comprehensiveness of our employee benefit programs versus the competitiveness of our products and solutions in the market and the associated profitability of those. So we did make the difficult decision during 2026 to discontinue financial support for GLP-1 drugs for weight management within our own employee health plan. And that coincides with broader availability of GLP-1 options that are now available in the market for individuals using the drugs for weight management, inclusive of the orals and tablets that you made reference to. We are offering a supplemental discount program to those employees who wish to pay out of pocket, and our clinical programs are available to support them. We'll continue to cover GLP-1s for diabetes within our own plan. Now, the decision that we made in our employee benefit plan is driven by the exact same set of challenges that many of our clients are facing, specifically where the net cost of the drug is straining the overall affordability of the plan. Now, of course, we'll continue to monitor this situation carefully. and should drug manufacturers decide to meaningfully discount the net prices they offer, we may revisit this in the future. Across our broader client base, we're seeing some of those same decisions being made and made reference to earlier a slight downtick in the percentage of our employers in Evernorth that are covering GLP-1s for late management and that produces a modest headwind to our 2026 results which fortunately was overwhelmed or was more than offset by the strength and specialty in the second quarter. And so overall, Evernorth results continue to deliver. As it relates to the GLP-1 coverage decision and the implications for our support programs, we continue to offer a variety of financing solutions for employers that range from fully covering the cost of the GLP-1 drugs to covering a portion of the costs to offering it on more of a sponsored or voluntary basis. So this space will certainly continue to evolve in the future. Our Encircle program continues to be very effective for those employers who do cover it for weight …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.